Free Trial

CorMedix Q3 2024 Earnings Report

CorMedix logo
$9.59 -0.26 (-2.64%)
(As of 02:21 PM ET)

CorMedix EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.05
One Year Ago EPS
-$0.17

CorMedix Revenue Results

Actual Revenue
$11.46 million
Expected Revenue
$11.00 million
Beat/Miss
Beat by +$460.00 thousand
YoY Revenue Growth
N/A

CorMedix Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Coins Set to Soar with a Pro-Crypto White House (Ad)

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

CorMedix Earnings Headlines

CorMedix supports CMS policy updates
Coins Set to Soar with a Pro-Crypto White House
Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…
See More CorMedix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

View CorMedix Profile

More Earnings Resources from MarketBeat